Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer

IntroductionThe Ets-1 transcription factor is a candidate breast cancer oncogene that regulates the expression of genes involved in tumor progression and metastasis. Ets-1 signaling has also been linked to the development of a basal-like breast cancer phenotype. We recently described a nitric oxide (NO)-induced gene signature that is associated with poor disease outcome in estrogen receptor-negative (ER-) breast cancer and contains both stem cell-like and basal-like components. Thus, we examined the role of Ets-1 in NO signaling and NO-induced phenotypes in ER- human breast cancer cells.MethodsPromoter region analyses were performed on genes upregulated in inducible nitric oxide synthase (NOS2) high expressing tumors for Ets-binding sites. In vitro mechanisms were examined in human basal-like breast cancer cells lines. NO signaling effects were studied using either forced NOS2 expression or the use of a chemical NO-donor, diethlylenetriamine NONOate (DETANO).ResultsPromoter region analysis of genes that are up-regulated in human ER-negative breast tumors with high NOS2 expression revealed that the Ets-binding sequence is the only common promoter element present in all of these genes, indicating that Ets-1 is the key transcriptional factor down-stream of oncogenic NOS2-signaling. Accordingly, both forced NOS2 over-expression and exposure to NO-donors resulted in significant Ets-1 transcriptional activation in ER- breast cancer cells. Functional studies showed that NO activated Ets-1 transcriptional activity via a Ras/MEK/ERK signaling pathway by a mechanism that involved Ras S-nitrosylation. RNA knock-down of Ets-1 suppressed NO-induced expression of selected basal-like breast cancer markers such as P-cadherin, S100A8, IL-8 and αβ-crystallin. Additionally, Ets-1 knock-down reduced NO-mediated cellular proliferation, matrix metalloproteinase and cathepsin B activities, as well as matrigel invasion.ConclusionsThese data show that Ets-1 is a key transcriptional mediator of oncogenic NO signaling that promotes the development of an aggressive disease phenotype in ER- breast cancer in an Ets-1 and Ras-dependent manner, providing novel clues of how NOS2 expression in human breast tumors is functionally linked to poor patient survival.

[1]  W. Kolch,et al.  Protein kinase C alpha activates RAF-1 by direct phosphorylation. , 1993, Nature.

[2]  K. M. Davies,et al.  "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. , 1996, Methods in enzymology.

[3]  S. Ambs,et al.  Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. , 2011, Trends in pharmacological sciences.

[4]  Michael P Vitek,et al.  Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways , 2007, Proceedings of the National Academy of Sciences.

[5]  C. Harris,et al.  Nitric Oxide and Cancer: An Overview , 2010 .

[6]  F. Soncin,et al.  Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth , 2005, Oncogene.

[7]  M. Abe,et al.  Ets‐1 regulates angiogenesis by inducing the expression of urokinase‐type plasminogen activator and matrix metalloproteinase‐1 and the migration of vascular endothelial cells , 1996, Journal of cellular physiology.

[8]  Nissi M. Varki,et al.  Ras activation in human breast cancer , 2000, Breast Cancer Research and Treatment.

[9]  A. Wellmann,et al.  The Ets‐1 transcription factor is up‐regulated together with MMP 1 and MMP 9 in the stroma of pre‐invasive breast cancer , 2001, The Journal of pathology.

[10]  Bin Li,et al.  S-Nitrosylation from GSNOR Deficiency Impairs DNA Repair and Promotes Hepatocarcinogenesis , 2010, Science Translational Medicine.

[11]  I. Hanbauer,et al.  Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH. Insights into the fate and physiological effects of intermediates generated in the NO/O2 reaction. , 1994, Chemical research in toxicology.

[12]  Kathleen Bove,et al.  The transcription factor Ets-1 in breast cancer. , 2005, Frontiers in bioscience : a journal and virtual library.

[13]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[14]  C. Sweep,et al.  Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer , 2002, Oncogene.

[15]  J. Lautenberger,et al.  Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETS1 antisense oligonucleotides. , 1997, Cancer research.

[16]  Toshiyuki Nakayama,et al.  Ets-1 proto-oncogene as a potential predictor for poor prognosis of lung adenocarcinoma. , 2007, The Tohoku journal of experimental medicine.

[17]  S. Ambs,et al.  Molecular mechanisms for discrete nitric oxide levels in cancer. , 2008, Nitric oxide : biology and chemistry.

[18]  B. Chait,et al.  Monitoring Reactions of Nitric Oxide with Peptides and Proteins by Electrospray Ionization-Mass Spectrometry (*) , 1995, The Journal of Biological Chemistry.

[19]  Walter Kolch,et al.  Protein kinase Cα activates RAF-1 by direct phosphorylation , 1993, Nature.

[20]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[21]  David P Turner,et al.  Defining ETS transcription regulatory networks and their contribution to breast cancer progression , 2007, Journal of cellular biochemistry.

[22]  R. Stephens,et al.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. , 2010, The Journal of clinical investigation.

[23]  N. Katunuma,et al.  Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. , 2005, The journal of medical investigation : JMI.

[24]  Guoyao Wu,et al.  Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. , 2007, Cancer research.

[25]  A. Buzaid,et al.  Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  A. Nordheim,et al.  Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. , 2003, International journal of oncology.

[27]  Michael C. Ostrowski,et al.  Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2 , 1996, Molecular and cellular biology.

[28]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Moyano,et al.  AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. , 2008, Annals of diagnostic pathology.

[31]  Lajos Pusztai,et al.  A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.

[32]  C. Harris,et al.  Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  F. Bertucci,et al.  Gene expression profiling of breast cell lines identifies potential new basal markers , 2006, Oncogene.

[34]  M. Duffy,et al.  Overexpression of the Ets-1 transcription factor in human breast cancer , 2004, British Journal of Cancer.

[35]  T. Pietsch,et al.  Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. , 2005, International journal of molecular medicine.

[36]  M. Duffy,et al.  Metalloproteinases: role in breast carcinogenesis, invasion and metastasis , 2000, Breast Cancer Research.

[37]  Dislodgment and accelerated degradation of ras , 1997, Neuroscience Letters.

[38]  Joseph R Evans,et al.  Regulation of αB-crystallin gene expression by the transcription factor Ets1 in breast cancer , 2009, Breast Cancer Research and Treatment.

[39]  B. Wasylyk,et al.  Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2 , 1997, Oncogene.

[40]  T. Senga,et al.  S-Nitrosylation at Cysteine 498 of c-Src Tyrosine Kinase Regulates Nitric Oxide-mediated Cell Invasion* , 2009, The Journal of Biological Chemistry.

[41]  E. Grimm,et al.  NO news is not necessarily good news in cancer. , 2005, Current cancer drug targets.

[42]  Solomon H. Snyder,et al.  The Biotin Switch Method for the Detection of S-Nitrosylated Proteins , 2001, Science's STKE.

[43]  B. Vandenbunder,et al.  Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway , 2002, Oncogene.

[44]  S. Ambs,et al.  Inflammation and IGF‐I activate the Akt pathway in breast cancer , 2007, International journal of cancer.

[45]  H. Sasaki,et al.  Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. , 2001, The Journal of surgical research.

[46]  Jürgen Dittmer,et al.  Molecular Cancer BioMed Central Review The Biology of the Ets1 Proto-Oncogene , 2003 .

[47]  D. Hajjar,et al.  Recruitment and activation of Raf-1 kinase by nitric oxide-activated Ras. , 2000, Biochemistry.

[48]  W. Kolch.  Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. , 2000, The Biochemical journal.

[49]  Bonnie F. Sloane,et al.  Cathepsin B inhibition limits bone metastasis in breast cancer. , 2012, Cancer research.

[50]  C. Rhee,et al.  Activation of Epidermal Growth Factor Receptor and Its Downstream Signaling Pathway by Nitric Oxide in Response to Ionizing Radiation , 2008, Molecular Cancer Research.

[51]  G. Chaudhuri,et al.  NO to breast: when, why and why not? , 2010, Current pharmaceutical design.

[52]  C. Harris,et al.  The chemical biology of nitric oxide: implications in cellular signaling. , 2008, Free radical biology & medicine.

[53]  C. Thomssen,et al.  Ets1 is an effector of protein kinase Cα in cancer cells , 2005, Oncogene.

[54]  J. Stamler,et al.  Glioma Stem Cell Proliferation and Tumor Growth Are Promoted by Nitric Oxide Synthase-2 , 2011, Cell.

[55]  C. Colton,et al.  Nitric oxide and redox mechanisms in the immune response , 2011, Journal of leukocyte biology.

[56]  A. Furlan,et al.  Ets‐1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment , 2008, Journal of cellular physiology.

[57]  B. Bonavida.  Nitric oxide (NO) and cancer , 2010 .

[58]  I. Giannopoulou,et al.  Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype. , 2006, Cancer detection and prevention.

[59]  C. Thomssen,et al.  Ets1 is an effector of protein kinase Calpha in cancer cells. , 2005, Oncogene.

[60]  E. Alba,et al.  Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer , 2010, BMC Cancer.

[61]  David R. Jones,et al.  S-nitrosoglutathione reductase in human lung cancer. , 2012, American journal of respiratory cell and molecular biology.

[62]  A. Bosserhoff,et al.  The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma , 2003, Cellular and Molecular Life Sciences CMLS.